Looking for an Ozempic® alternative?

The same proven GLP-1 medicine. A fraction of the price.

Ozempic® is approved for type 2 diabetes, so cash-pay weight-loss patients face roughly $1,000+ a month and persistent shortages. AvataCore connects you with a licensed U.S. provider for a compounded semaglutide plan — the same GLP-1 class studied in the STEP-1 trial — starting at transparent intro pricing.

$149

AvataCore intro price

14.9%

Avg. trial loss (GLP-1)

1–2 day

Free shipping

See if I Qualify →2-min quiz · No card required · Same-day provider review
LegitScript Healthcare CertifiedLicensed U.S. compounding pharmacies100% US-licensed providersFree 1–2 day shippingCancel anytime

The part nobody explains clearly

It starts with proven GLP-1 medicine

The brand-name product you were looking for and AvataCore's plan both use a GLP-1 medication prescribed by a licensed provider — though they are different products, prepared differently.

The GLP-1 medication class

Semaglutide (GLP-1)

Studied in STEP-1 (NEJM 2021)

two ways to get it

The branded route

Ozempic® · Novo Nordisk

$1,149+ /mo cash, without insurance

  • Priced and stocked for diabetes, not cash weight-loss patients
  • Ongoing shortages and pharmacy runarounds
  • Insurance rarely covers it for weight loss
  • One fixed pen, one fixed dose ladder
The AvataCore route

Prepared for you

Compounded by a licensed U.S. pharmacy on your provider's Rx

$149 first 4 weeks · intro pricing

  • In stock — no shortage runaround
  • No insurance, no prior auth required
  • Dose personalized & titrated by your provider
  • Provider care, messaging & free shipping included

Compounded medications are not FDA-approved and are not the same as FDA-approved branded products. AvataCore is not affiliated with Novo Nordisk or Eli Lilly. Eligibility is determined by a licensed provider.

Landmark clinical trials

What the science actually shows

Published results from the NEJM STEP-1 and SURMOUNT-1 trials of these GLP-1 medication classes. Trials studied branded products; compounded medications are not FDA-approved. Individual results vary.

Diet & exercise alone2.4%
Semaglutide (GLP-1) — STEP-114.9%
Tirzepatide (GLP-1+GIP) — SURMOUNT-120.9%

Why patients make the switch

Built for you, not for a factory

A brand-name pen ships one fixed strength to everyone. Because your medication is compounded on a provider's prescription, everything adjusts to you.

💸

A fraction of the cash price

Branded semaglutide pens run around four figures a month without coverage. Your compounded plan starts at intro pricing with provider care and free shipping included.

📦

In stock and shipped to you

No pharmacy scavenger hunt. Your medication is prepared by a licensed U.S. pharmacy and ships to your door, typically in 1–2 days.

🎯

Care that adjusts with you

Your provider personalizes your starting dose and titration, with unlimited clinical messaging included as your body adjusts.

Start the 2-min quiz →

No card required · Same-day review · Cancel anytime

From quiz to delivery

What happens after you qualify

No phone calls, no insurance forms, no waiting room. The whole process is online.

01

Take the quiz

2 minutes. No card required. Shares your health history and goals with a licensed provider.

02

Provider review

A licensed U.S. provider reviews your intake — typically same day.

03

Rx to pharmacy

If you qualify, your prescription goes directly to a licensed 503A compounding pharmacy.

04

Delivered in days

Your medication ships to your door in 1–2 days, free, with dosing instructions.

Common questions

Things people ask before starting

Is this the same as Ozempic®?+

No. Compounded semaglutide is not Ozempic® and is not FDA-approved. It is a different product, prepared by a licensed U.S. compounding pharmacy on your provider’s prescription. What it shares with Ozempic® is the medication class — semaglutide, a GLP-1 receptor agonist — the same class studied in the landmark STEP-1 trial.

Ozempic® is for diabetes — what about weight loss?+

AvataCore’s program is for medically supervised weight management. A licensed U.S. provider reviews your history and goals and determines whether a compounded semaglutide plan is appropriate for you.

Why is it so much less expensive?+

You are not paying for a branded, mass-manufactured pen or its marketing. A compounding pharmacy prepares your medication on a provider’s prescription, priced transparently with provider care and shipping included.

Is compounded semaglutide safe?+

Compounded medications are prepared by licensed U.S. pharmacies under state board oversight and 503A regulation, following USP 795/797 standards. They are different from FDA-approved branded products and have not been evaluated by the FDA for safety, efficacy, or quality. A licensed provider determines whether treatment is appropriate for you.

Ready to start?

A licensed provider reviews every intake and determines eligibility based on your medical history and weight-management goals. No card required to see if you qualify.

No card required to qualifySame-day provider reviewCancel anytime
Start a compounded GLP-1 plan — $149

Plans start at $149 for your first 4 weeks · Subscription auto-renews monthly until cancelled

Important: Compounded medications are NOT FDA-approved and are different from FDA-approved branded products such as Ozempic®, Wegovy®, Zepbound®, and Mounjaro®. They are prepared by licensed U.S. pharmacies under 503A regulation and have not been evaluated by the FDA for safety, efficacy, or quality. Brand pricing reflects publicly available retail cash estimates and is subject to change. AvataCore is not affiliated with Novo Nordisk or Eli Lilly. Eligibility for treatment is determined by a licensed provider.

Trademark notice: Wegovy® and Ozempic® are registered trademarks of Novo Nordisk. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly. AvataCore is not affiliated with, endorsed by, or sponsored by either manufacturer.

Clinical trial data cited: Wilding et al., NEJM 2021 (STEP-1, semaglutide 2.4 mg, 68 wks); Jastreboff et al., NEJM 2022 (SURMOUNT-1, tirzepatide 15 mg, 72 wks). Trials studied FDA-approved branded products; compounded medications are not FDA-approved. Individual results vary. Brand pricing reflects publicly available retail estimates and is subject to change.